Chapter title |
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
|
---|---|
Chapter number | 13 |
Book title |
Translational Research in Breast Cancer
|
Published in |
Advances in experimental medicine and biology, January 2017
|
DOI | 10.1007/978-981-10-6020-5_13 |
Pubmed ID | |
Book ISBNs |
978-9-81-106019-9, 978-9-81-106020-5
|
Authors |
Hitomi Sumiyoshi Okuma, Kan Yonemori, Okuma, Hitomi Sumiyoshi, Yonemori, Kan |
Abstract |
Breast cancer is the most common cancer in women worldwide. Treatment is chosen according to its hormone receptor status and human epidermal growth factor receptor 2 (HER2) status. Among the four main clinically set subtypes, hormone receptor-negative/HER2-negative subtype, also called triple-negative subtype (TNBC), is the most aggressive type with limited choices of therapy. However, recent research has provided important new insights into effective treatments for this subtype. One molecular target that has gained attention is the BRCA gene. BRCA proteins are involved in the maintenance of genomic integrity, therefore playing an important role as a "caretaker" DNA repair protein. Approximately 5% of all breast cancer patients are BRCA mutation carriers, and among the patients with BRCA mutations, 57.1% have the clinical TNBC subtype, showing a high association between BRCA mutations and TNBCs. When cells lack either BRCA1 or BRCA2, all types of homology-directed repairs are compromised, and poly(ADP-ribose) (PAR) polymerase (PARP) acts as a backup system to maintain the genome, consequently making the cells highly sensitive to PARP1 inhibitors. PARP inhibitors have shown promising activity in preclinical and early clinical trials, and today, phase III trials are ongoing. In this chapter, we discuss the mechanism and the role of PARP inhibitors in BRCA-mutated breast cancers and further elaborate the clinical potential of PARP inhibitors as well as their barriers. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 40% |
United States | 1 | 20% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Scientists | 2 | 40% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 37 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 24% |
Student > Bachelor | 7 | 19% |
Student > Ph. D. Student | 7 | 19% |
Researcher | 3 | 8% |
Other | 2 | 5% |
Other | 2 | 5% |
Unknown | 7 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 32% |
Biochemistry, Genetics and Molecular Biology | 10 | 27% |
Agricultural and Biological Sciences | 3 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
Social Sciences | 1 | 3% |
Other | 1 | 3% |
Unknown | 7 | 19% |